Healthcare [ 13/13 ] | Biotechnology [ 106/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 2, 23 | -0.39 Increased by +22% | -0.42 Increased by +7.14% |
| Aug 3, 23 | -0.48 Increased by +30.43% | -0.45 Decreased by -6.67% |
| May 4, 23 | -0.44 Increased by +36.23% | -0.46 Increased by +4.35% |
| Feb 15, 23 | -0.37 Increased by +59.78% | -0.54 Increased by +31.48% |
| Nov 3, 22 | -0.5 Increased by +30.56% | -0.53 Increased by +5.66% |
| Aug 4, 22 | -0.69 Decreased by -15% | -0.73 Increased by +5.48% |
| May 5, 22 | -0.69 Decreased by -38% | -0.8 Increased by +13.75% |
| Feb 10, 22 | -0.92 Decreased by -170.59% | -0.81 Decreased by -13.58% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -44.27 M Decreased by -7.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -45.27 M Decreased by -1.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -39.13 M Increased by +12.12% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -38.14 M Increased by +34.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -41.19 M Increased by +9.48% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -44.64 M Decreased by -18.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -44.53 M Decreased by -44.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -57.94 M Decreased by -129.93% | Decreased by N/A% Decreased by N/A% |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.